Oncolytics Biotech Inc ONCY

Primary Symbol: T.ONC

Healthcare Biotechnology

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.

TSX:ONC - Post by User

Oncolytics Biotech Inc > Seagen filed SEC Schedule 14A outlining Pfizer $43 Bln M&A

<< Previous

Bullboard Posts

Next >>

Comment by fasttrack5on Jul 27, 2023 10:06am

113 Views

Post# 35559387

RE:RE:RE:RE:Seagen filed SEC Schedule 14A outlining Pfizer $43 Bln M&A

Noteable wrote: July 25, 2023 - FTC withdraws advocacy for pharmacy benefit managers

"Claiming that its old policy statements no longer reflect current market dynamics, the Federal Trade Commission has voted to rescind its prior statements of advocacy for pharmacy benefit managers, effectively ending the agency's previously stated endorsement of PBMs.

According to the FTC, the new statement pulling its advocacy is a response to PBMs' continued reliance on older FTC advocacy materials that opposed mandatory PBM transparency and disclosure requirements.

It also warns against reliance on the Commission's prior conclusions, particularly given the FTC's ongoing study of the PBM industry to update its understanding of the industry and its practices."

https://www.healthcarefinancenews.com/news/ftc-withdraws-advocacy-pharmacy-benefit-managers